Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+NSCLC Patients

被引：78

作者：

Kowanetz, Marcin ^{[1
]}

Zou, Wei ^{[1
]}

Shames, David ^{[1
]}

Cummings, Craig ^{[1
]}

Rizvi, Naiyer ^{[2
]}

Spira, Alexander ^{[3
,4
]}

Frampton, Garrett ^{[5
]}

Leveque, Vincent ^{[1
]}

Flynn, Susan ^{[1
]}

Mocci, Simonetta ^{[1
]}

Shankar, Geetha ^{[1
]}

Funke, Roel ^{[1
]}

Ballinger, Marcus ^{[1
]}

Waterkamp, Daniel ^{[1
]}

Chen, Daniel ^{[1
]}

Sandler, Alan ^{[1
]}

Hampton, Garret ^{[1
]}

Amler, Lukas ^{[1
]}

Hegde, Priti ^{[1
]}

Hellmann, Matthew ^{[6
]}

机构：

[1] Genentech Inc, San Francisco, CA 94080 USA

[2] Columbia Univ, New York, NY USA

[3] US Oncol Res, The Woodlands, TX USA

[4] Virginia Canc Specialists Res Inst, Fairfax, VA USA

[5] Fdn Med, Cambridge, MA USA

[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

Immunotherapy; mutational load; NSCLC; Biomarkers;

D O I：

10.1016/j.jtho.2016.11.343

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA20.01

引用

页码：S321 / S322

页数：2

共 50 条

[11] Tumor mutational burden (TMB) and PD-L1 expression as predictors of response to immunotherapy (IO) in NSCLC.
Castellanos, Emily
Snider, Jeremy
Ali, Siraj Mahamed
Backenroth, Daniel
Albacker, Lee A.
Murugesan, Karthikeyan
Li, Gerald
Frampton, Garrett M.
Alexander, Brian Michael
Carson, Kenneth Robert
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[12] IMpower150: Impact of Chemotherapy Cycles in 1L Metastatic NSCLC in Patients Treated With Atezolizumab plus Bevacizumab
Rothenstein, J.
Spira, A.
Velcheti, V.
Natale, R.
Kozloff, M.
Kosty, M.
Goldschmidt, J., Jr.
Mazieres, J.
Ponce Aix, S.
Yu, W.
Gandhi, M.
Lee, A.
Shankar, G.
Lin, W.
Thomas, C.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S495 - S495
[13] Atezolizumab as 1L Therapy for Advanced NSCLC in PD-L1 Selected Patients: Updated ORR, PFS and OS Data from the BIRCH Study
Garassino, Marina
Rizvi, Naiyer
Besse, Benjamin
Janne, Pasi
Christoph, Daniel
Peters, Solange
Toh, Chee Keong
Kurata, Takayasu
Carcereny Costa, Enric
Koczywas, Marianna
Felip, Enriqueta
Chaft, Jamie
Qiu, Jiaheng
Kowanetz, Marcin
Coleman, Shelley
Mocci, Simonetta
Sandler, Alan
Gettinger, Scott
Johnson, Melissa
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S251 - S252
[14] Atezolizumab as 1L therapy for advanced NSCLC in PD-L1-selected patients: updated ORR, PFS and OS data from the BIRCH study
Eberhardt, W. E. E.
Garassino, M. C.
Rizvi, N. A.
Janne, P. A.
Christoph, D.
Peters, S.
Toh, C. K.
Kurata, T.
Costa, E. C.
Koczywas, M.
Felip, E.
Chaft, J.
Qiu, J.
Kowanetz, M.
Coleman, S.
Mocci, S.
Sandler, A.
Gettinger, S.
Johnson, M. L.
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 220 - 220
[15] IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1-Selected Chemotherapy Naive NSCLC Patients
Herbst, Roy S.
De Marinis, Filippo
Jassem, Jacek
Lam, Sivuonthanh
Mocci, Simonetta
Sandler, Alan
Lopez-Chavez, Ariel
Deng, Yu
Giaccone, Giuseppe
Spigel, David R.
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S304 - S305
[16] IMpower110: Phase III trial of 1L atezolizumab in PD-L1-selected chemotherapy-naive NSCLC
Jassem, J.
de Marinis, F.
Spigel, D. R.
Lam, S.
Mocci, S.
Sandler, A.
Lopez-Chavez, A.
Deng, Y.
Giaccone, G.
Herbst, R. S.
ANNALS OF ONCOLOGY, 2017, 28
[17] IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1 Selected Chemotherapy-Naive NSCLC Patients
De Marinis, Filippo
Jassem, Jacek
Spige, David
Lam, Sivuonthanh
Mocci, Simonetta
Sandler, Alan
Lopez-Chavez, Ariel
Deng, Yu
Giacconne, Giuseppe
Herbst, Roy
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1299 - S1300
[18] IMpower110: Phase III study on 1L atezolizumab (atezo) in PD-L1-selected chemotherapy (chemo)-naive NSCLC patients (pts)
De Marinis, F.
Jassem, J.
Spigel, D. R.
Lam, S.
Mocci, S.
Sandler, A.
Lopez-Chavez, A.
Deng, Y.
Giaccone, G.
Herbst, R. S.
ANNALS OF ONCOLOGY, 2016, 27
[19] PD-L1, Tumor Mutational Burden (TMB) and Intracranial Outcomes in Patients with Non -Small Cell Lung Cancer (NSCLC) and Brain Metastases
Adib, E.
Nassar, A. H.
Kwiatkowski, D. J.
Aizer, A. A.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E213 - E213
[20] IMpower110: Exploratory analyses of the impact of first-line (1L) atezolizumab on the efficacy of next-line of therapy in PD-L1eselected NSCLC
Patel, S. P.
Reuss, J. E.
Scilla, K.
Giaccone, G.
Spigel, D. R.
Ngiam, C.
Zhu, Q.
Bara, I.
Ding, B.
Herbst, R. S.
ANNALS OF ONCOLOGY, 2021, 32 : S1398 - S1399

← 1 2 3 4 5 →